Premium
Lipid changes during basal insulin peglispro, insulin glargine, or NPH treatment in six IMAGINE trials
Author(s) -
Ginsberg Henry,
Cariou Bertrand,
Orchard Trevor,
Chen Lei,
Luo Junxiang,
Bastyr Edward J.,
BueValleskey Juliana,
Chang Annette M.,
Ivanyi Tibor,
Jacober Scott J.,
Hoogwerf Byron J.
Publication year - 2016
Publication title -
diabetes, obesity and metabolism
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.445
H-Index - 128
eISSN - 1463-1326
pISSN - 1462-8902
DOI - 10.1111/dom.12754
Subject(s) - basal insulin , insulin glargine , basal (medicine) , insulin , endocrinology , medicine , nph insulin , diabetes mellitus , chemistry , type 2 diabetes , hypoglycemia
Basal insulin peglispro ( BIL ) is a novel basal insulin with hepato‐preferential action resulting from reduced peripheral effects. This report provides an integrated summary of lipid changes at 26 weeks with BIL and comparator insulins (glargine, NPH ) from phase III studies in type 1 diabetes ( T1D ), insulin‐naïve patients with type 2 diabetes ( T2D ), patients with T2D on basal insulin only and patients with T2D on basal‐bolus therapy. BIL treatment had little effect on HDL cholesterol and LDL cholesterol in all patients. The effect of both BIL and glargine treatment on triglycerides ( TG ) depended on whether patients had been previously treated with insulin. When BIL replaced conventional insulin glargine or NPH treatments, increases in TG levels were observed. When BIL or comparator insulins were given for 26 weeks to insulin‐naïve patients with T2D , TG levels were unchanged from baseline with BIL but decreased with either glargine or NPH . The decreased peripheral action of BIL may reduce suppression of lipolysis in peripheral adipose tissue resulting in increased free fatty acid delivery to the liver and, hence, increased hepatic TG synthesis and secretion.